Skip to main content
. 2024 Mar 14;7(1):59–67. doi: 10.1159/000538311

Table 1.

Overall patient (N = 11,883) characteristics stratified according to survival time (time of SAPC therapy from start to death)

Parameter Category Survival time (from SAPC start to death) p value
<7 days, N (%)/Med (IQR) 7–100 days, N (%)/Med (IQR) >100 days, N (%)/Med (IQR)
Patients 2,464 (100) 7,085 (100) 2,334 (100)
Center A 466 (18.9) 1,265 (17.9) 491 (21) <0.001
B 390 (15.8) 914 (12.9) 308 (13.2)
C 983 (39.9) 3,263 (46.1) 1,087 (46.6)
D 598 (24.3) 1,548 (21.8) 425 (18.2)
E 27 (1.1) 95 (1.3) 23 (1)
Age, years Med (IQR) 80 (72–87) 77 (66–83) 74 (63–81) <0.001
Age group <56 years 129 (5.2) 668 (9.4) 287 (12.3) <0.001
>75 years 1,629 (66.1) 3,842 (54.2) 1,073 (46)
56–65 years 254 (10.3) 989 (14) 438 (18.8)
66–75 years 452 (18.3) 1,586 (22.4) 536 (23)
Gender Female 1,199 (48.7) 3,332 (47) 1,133 (48.5) 0.240
Male 1,265 (51.3) 3,753 (53) 1,201 (51.5)
Leading symptoms Pain 1,487 (60.3) 4,518 (63.8) 1,422 (60.9) 0.002
Urology 214 (8.7) 714 (10.1) 293 (12.6) <0.001
Cardiorespiratory 1,017 (41.3) 2,439 (34.4) 769 (32.9) <0.001
Gastrointestinal 630 (25.6) 2,576 (36.4) 825 (35.3) <0.001
Wound 169 (6.9) 525 (7.4) 195 (8.4) 0.135
Neuropsychiatric 1,289 (52.3) 3,463 (48.9) 1,104 (47.3) 0.001
Other severe symptoms 1,793 (72.8) 4,817 (68) 1,565 (67.1) <0.001
Survival time, days Med (IQR) 3 (2–5) 25 (13–49) 209 (139–369) <0.001
THC No 2,446 (99.3) 6,875 (97) 2,234 (95.7) <0.001
Yes 18 (0.7) 210 (3) 100 (4.3)
THC dose, mg/day Med (IQR) 2.4 (2.4–4.8) 4.7 (2.4–7.2) 6.8 (3.2–9.6) <0.001
THC dose ≤4.7 mg/day 13 (72.2) 105 (50) 32 (32) <0.001
>4.7 mg/day 5 (27.8) 105 (50) 68 (68)

Med, median; IQR, interquartile range; N, number; THC, tetrahydrocannabinol.